［1］Pisano C，Bruni GS，Facchini G，et al.Treatment of recurrent epithelial ovarian cancer［J］.Clin Risk Manag，2009，5：421-426.
［2］Rudaitis V，Zvirblis T，Kanopiene D，et al.BRCA1/2 mutation status is an independent factor of improved survival for advanced(stage III-IV）ovarian cancer［J］.Int J Gynecol Cancer，2014，24(8)：1395-1400.
［3］Omar HA，Berman-Booty L，Weng JR.Energy restriction：stepping stones towards cancer therapy［J］.Future Oncol，2012，8(12)：1503-1506.
［4］Zhao Y，Butler EB，Tan M.Targeting cellular metabolism to improve cancer therapeutics［J］.Cell Death Dis，2013，4：e532.
［5］Gong L，Cui Z，Chen P，et al.Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II［J］.Med Oncol，2012，29(2)：909-914.
［6］Agnihotri S，Micallef J.Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme［J］.J Exp Med，2011，208(2)：313-326.
［7］Wang L，Xiong H，Wu F，et al.Hexokinase 2-mediated Warburg effect is required for PTEN-and p53-deficiency-driven prostate cancer growth［J］.Cell Rep，2014，8(5)：461-474.
［8］Wei J，Ma Z，Li Y，et al.miR 143 inhibits cell proliferation by targeting autophagy related 2B in non small cell lung cancer H1299 cells［J］.Mol Med Rep，2015，11(1)：571-657.
［9］Jin Z，Gu J，Xin X，et al.Expression of hexokinase 2 in epithelial ovarian tumors and its clinical significance in serous ovarian cancer［J］.Eur J Gynaecol Oncol，2014，35(5)：519-524.
［10］Zakharia Y，Rahma O，Khleif SN.Ovarian cancer from an immune perspective［J］.Radiat Res，2014，182(2)：239-251.
［11］Lisianskaia AS.Rationale for the approach to the choice of hormone therapy for ovarian cancer［J］.Vopr Onkol，2014，60(3)：274-279.
［12］Jang M，Kim SS，Lee J.Cancer cell metabolism：implications for therapeutic targets［J］.Exp Mol Med，2013，45：e45.
［13］Patra KC，Hay N.Hexokinase 2 as oncotarget［J］.Oncotarget，2013，4(11)：1862-1863.
［14］Sato-Tadano A，Suzuki T，Amari M，et al.Hexokinase II in breast carcinoma：a potent prognostic factor associated with hypoxia-inducible factor-1α and Ki-67［J］.Cancer Sci，2013，104(10)：1380-1388.
［15］Hamabe A，Yamamoto H，Konno M，et al.Combined evaluation of Hexokinase 2 and phosphorylated pyruvate dehydrogenase-E1α in invasive front lesions of colorectal tumors predicts cancer metabolism and patient prognosis［J］.Cancer Sci，2014，105(9)：1100-1108.
［16］Kang F，Ma W，Ma X，et al.Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2［J］.J Nucl Med，2014，55(3)：439-445.
［17］Krasnov GS，Dmitriev AA，Lakunina VA，et al.Targeting VDAC-bound hexokinase II：a promising approach for concomitant anti-cancer therapy［J］.Expert Opin Ther Targets，2013，17(10)：1221-1233.
［18］Zhang Q，Zhang Y，Zhang P，et al.Hexokinase II inhibitor，3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells［J］.Genes Cancer，2014，5(3-4)：100-112.
［19］Patra KC，Wang Q，Bhaskar PT，et al.Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer［J］.Cancer Cell，2013，24(2)：213-228.
［20］Gong L，Wei Y，Yu X，et al.3-Bromopyruvic acid，a hexokinase II inhibitor，is an effective antitumor agent on the hepatoma cells：in vitro and in vivo findings［J］.Anticancer Agents Med Chem，2014，14(5)：771-776.
［21］Yoshino H，Enokida H，Itesako T，et al.Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in renal cell carcinoma［J］.Cancer Sci，2013，104(12)：1567-1574.
［22］Kim JE，Ahn BC，Hwang MH，et al.Combined RNA interference of hexokinase II and(131)I-sodium iodide symporter gene therapy for anaplastic thyroid carcinoma［J］.J Nucl Med，2011，52(11)：1756-1763.
［23］Min JW，Kim KI，Kim HA，et al.INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells［J］.Biochem Biophys Res Commun，2013，440(1)：137-142.